nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,id,nct_id,name,downcase_name,intervention_type,intervention_name,description,intervention_count,status,facility_name,city,state,zip,country,site_count
"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-01T00:05:12Z,2020-03-01T00:05:12Z,3707775,NCT04275245,2019-nCoVs Infection Pneumonia,2019-ncovs infection pneumonia,Drug,Meplazumab for Injection,humanized MAb against CD147,1,Recruiting,Tangdu Hospital,Xi'an,Shaanxi,710032,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-07T05:29:32Z,2020-03-07T05:29:32Z,3875551,NCT04282902,Novel Coronavirus Pneumonia,novel coronavirus pneumonia,Drug,pirfenidone,"Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer",1,Recruiting,Tongji hospital affiliated to huazhong university of science and technology,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-22,NA,NA,2020-02-22,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-22,2020-02-25,Actual,"January 31, 2020",Actual,2020-01-31,February 2020,2020-02-29,"February 18, 2020",Actual,2020-02-18,"February 18, 2020",Actual,2020-02-18,NA,Observational,NA,,CT Scores Predict Mortality in 2019-nCoV Pneumonia,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Completed,NA,NA,39,Actual,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-07T05:28:52Z,2020-03-07T05:28:52Z,3875377,NCT04284046,CT Scores Predict Mortality in 2019-nCoV Pneumonia,ct scores predict mortality in 2019-ncov pneumonia,Other,CT score,CT score = normal lung tissue (%) Ã—1 + GGO (%) Ã—2 + consolidation (%) Ã—3,1,,Wuhan third hospital,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-15,NA,NA,2020-03-17,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"March 16, 2021",Anticipated,2021-03-16,"March 16, 2021",Anticipated,2021-03-16,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://errs.regeneron.com/external,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-03-29T09:09:12Z,2020-03-29T09:09:12Z,4270657,NCT04315298,COVID-19,covid-19,Drug|Drug,Sarilumab|Placebo,Single intravenous (IV) dose of sarilumab|Single intravenous (IV) dose of placebo to match sarilumab administration,2,Recruiting,Regeneron Study Site,New York,New York,10029,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-16,NA,NA,2020-03-16,2020-03-16,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-19,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 1, 2020",Anticipated,2020-05-01,3 Weeks,Observational [Patient Registry],NA,,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,NA,80,Anticipated,Xiangya Hospital of Central South University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-29T09:09:49Z,2020-03-29T09:09:49Z,4270832,NCT04314271,Novel Coronavirus Pneumonia,novel coronavirus pneumonia,NA,NA,NA,NA,Recruiting,"Xiangya Hospital, Central South University",Changsha,Hunan,410000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-17,NA,NA,2020-03-17,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID MECH,,Mechanisms to Morbidity and Mortality for Covid-19,"Changes in Organ Specific Biomarkers, Virus Expression and Prognosis for Covid-19",Not yet recruiting,NA,NA,200,Anticipated,"University Hospital, Akershus",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-29T09:09:50Z,2020-03-29T09:09:50Z,4270836,NCT04314232,Coronavirus,coronavirus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-21,NA,NA,2020-03-15,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,February 2020,Anticipated,2020-02-29,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19",Withdrawn,NA,N/A,0,Actual,The First Affiliated Hospital of Guangzhou Medical University,,2,NA,Without CDE Approval,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:22:39Z,2020-03-27T09:22:39Z,4241305,NCT04287686,COVID-19,covid-19,Drug,Recombinant human angiotensin-converting enzyme 2 (rhACE2),"In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.",1,,GCP Office of The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,510120,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Healthcare Workers in Coronavirus Disease 2019,The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,1,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-27T09:22:48Z,2020-03-27T09:22:48Z,4241346,NCT04283838,Coronavirus Disease 2019,coronavirus disease 2019,Behavioral,Humanistic Care,Psychological and physical rehabilitation based humanistic care regimen,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Patients With Coronavirus Disease 2019,The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,2,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-27T09:22:49Z,2020-03-27T09:22:49Z,4241347,NCT04283825,Coronavirus Disease 2019,coronavirus disease 2019,Behavioral,Psychological and physical rehabilitation based humanistic care,"This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-12,NA,NA,2020-03-13,2020-02-14,2020-02-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"January 25, 2020",Actual,2020-01-25,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"March 31, 2020",Anticipated,2020-03-31,NA,Observational,NA,,Prognositc Factors in COVID-19 Patients Complicated With Hypertension,Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China,Withdrawn,NA,NA,0,Actual,Chongqing Medical University,,NA,2,"Similar projects have been registered, and it need to be withdrawn.",FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:23:25Z,2020-03-27T09:23:25Z,4241463,NCT04272710,2019-nCoV,2019-ncov,NA,NA,NA,NA,,The First Affiliated Hospital of Chongqing Medical University,Chongqing,,,China,1
"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-07,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-07,2020-02-11,Actual,"February 7, 2020",Actual,2020-02-07,February 2020,2020-02-29,"August 7, 2023",Anticipated,2023-08-07,"August 7, 2020",Anticipated,2020-08-07,NA,Observational,CCP-nCoV,,Clinical Characterisation Protocol for Severe Emerging Infections,Clinical Characterisation Protocol for Severe Emerging Infections,Recruiting,NA,NA,500,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, urine, stool /rectal swab, respiratory samples (nose and throat swab, endotracheal
      aspirate, nasopharyngeal aspirate), samples from infected sites/sores, CSF
    ",NA,NA,NA,Undecided,NA,2020-02-25T23:41:22Z,2020-02-25T23:41:22Z,3093663,NCT04262921,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting|Recruiting|Recruiting|Recruiting,"CHU Pellegrin, service des Maladies Infectieuses et Tropicales|APHP La PitiÃ© SalpÃªtriÃ¨re, service des Maladies Infectieuses et Tropicales|APHP Bichat, Service de rÃ©animation mÃ©dicale et infectieuse|APHP Bichat, Service des Maladies Infectieuses et Tropicales",Bordeaux|Paris|Paris|Paris,|||,33075|75013|75018|75018,France|France|France|France,4
"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-02-25T23:42:31Z,2020-02-25T23:42:31Z,3095031,NCT04252885,Coronavirus Infections,coronavirus infections,Drug|Drug,Lopinavir and Ritonavir Tablets|Arbidol,As indicated in arm/group descriptions|As indicated in arm/group descriptions,2,Recruiting,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong,510060,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-09,NA,NA,2020-03-17,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Sars-CoV2 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-29T09:10:37Z,2020-03-29T09:10:37Z,4271016,NCT04304690,Sars-CoV2,sars-cov2,Other,blood sample,2 blood samples at T0 and 3 months,1,Recruiting,Hopital PitiÃ© SalpetriÃ¨re,Paris,,75013,France,1
"ClinicalTrials.gov processed this data on February 27, 2020",2020-02-16,NA,NA,2020-02-16,2020-02-16,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-18,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,July 2020,Anticipated,2020-07-31,May 2020,Anticipated,2020-05-31,NA,Observational,NA,,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC),Not yet recruiting,NA,NA,100,Anticipated,Peking University Third Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-29T00:07:37Z,2020-02-29T00:07:37Z,3691541,NCT04274322,Coronavirus Infections,coronavirus infections,Other,Nutrition support,"Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-20,NA,NA,2020-03-17,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"February 22, 2020",Actual,2020-02-22,March 2020,2020-03-31,"March 31, 2020",Anticipated,2020-03-31,"March 31, 2020",Anticipated,2020-03-31,NA,Observational,NA,,Clinical Outcomes of Patients With COVID19,Clinical Outcomes of Hospitalized Patients With Coronavirus Disease 2019,Withdrawn,NA,NA,0,Actual,Guangzhou Institute of Respiratory Disease,,NA,1,The research project was changed.,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-29T09:11:25Z,2020-03-29T09:11:25Z,4271212,NCT04280913,Coronavirus Disease 2019,coronavirus disease 2019,Other,retrospective analysis,The investigators retrospectively analyzed the hospitalized patients with COVID-19.,1,,HuiZhou Municipal Central Hospital,Huizhou,Guangdong,516001,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-29T09:11:30Z,2020-03-29T09:11:30Z,4271233,NCT04276896,Pathogen Infection Covid-19 Infection,pathogen infection covid-19 infection,Biological,Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,"Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.",1,Recruiting|Recruiting|Recruiting,Shenzhen Geno-immune Medical Institute|Shenzhen Second People's Hospital|Shenzhen Third People's Hospital,Shenzhen|Shenzhen|Shenzhen,Guangdong|Guangdong|Guangdong,518000|518000|518000,China|China|China,3
"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-14,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-01T00:05:05Z,2020-03-01T00:05:05Z,3707740,NCT04275414,Coronavirus Infections,coronavirus infections,Drug,Bevacizumab Injection,"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip â‰¥90min",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:24:04Z,2020-03-27T09:24:04Z,4241621,NCT04255017,2019-nCoV,2019-ncov,Drug|Drug|Drug,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,"Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 05, 2020",2020-02-15,NA,NA,2020-02-20,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Recruiting,NA,N/A,400,Anticipated,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-06T05:31:45Z,2020-03-06T05:31:45Z,3840778,NCT04273321,COVID-19,covid-19,Drug,Methylprednisolone,Methylprednisolone 1mg/kg/day ivgtt for 7 days.,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Hubei province hospital of integrated Chinese & Western Medicine|Yichang first people's Hospital|Renmin Hospital of Wuhan University|Tianyou Hospital Affiliated to Wuhan University of science and technology|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology,Wuhan|Yichang|Wuhan|Wuhan|Wuhan,Hubei|Hubei|||,||||,China|China|China|China|China,5
"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-07,Actual,"February 10, 2020",Anticipated,2020-02-10,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia,"A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia",Not yet recruiting,NA,Phase 2/Phase 3,80,Anticipated,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-02-25T23:41:31Z,2020-02-25T23:41:31Z,3093854,NCT04261426,2019-nCoV,2019-ncov,Drug|Other,Intravenous Immunoglobulin|Standard care,IVIG 0.5g/kg/d for 5 days|Standard care,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-28T09:18:43Z,2020-03-28T09:18:43Z,4255970,NCT04313322,Use of Stem Cells for COVID-19 Treatment,use of stem cells for covid-19 treatment,Biological,WJ-MSCs,"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.",1,Recruiting,Stem Cells Arabia,Amman,,11953,Jordan,1
"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-15,NA,NA,2020-03-02,2020-03-02,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-02,2020-03-03,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon Î±1Î² in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Not yet recruiting,NA,Early Phase 1,328,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-14T09:29:16Z,2020-03-14T09:29:16Z,4063708,NCT04293887,COVID-19,covid-19,Drug,Recombinant human interferon Î±1Î²,Saline needle 2ml + recombinant human interferon Î±1Î²10ug bid nebulization inhalation,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 05, 2020",2020-01-31,NA,NA,2020-02-20,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 12, 2020",Actual,2020-02-12,February 2020,2020-02-29,"April 27, 2020",Anticipated,2020-04-27,"April 10, 2020",Anticipated,2020-04-10,NA,Interventional,NA,,Mild/Moderate 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.",Recruiting,NA,Phase 3,308,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-06T05:32:54Z,2020-03-06T05:32:54Z,3841043,NCT04252664,2019-nCoV,2019-ncov,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Jin Yin-tan hospital,Wu Han,Hubei,100013,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-14,NA,NA,2020-03-14,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Observational,NA,,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,Not yet recruiting,NA,NA,100,Anticipated,Huashan Hospital,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-27T09:20:15Z,2020-03-27T09:20:15Z,4240701,NCT04311398,COVID-19,covid-19,Diagnostic Test,New QIAstat-Dx fully automatic multiple PCR detection platform,We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients,1,,Huashan Hospital of Fudan University,Shanghai,Shanghai,200040,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"June 30, 2021",Anticipated,2021-06-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",Not yet recruiting,NA,Phase 2/Phase 3,116,Anticipated,China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:20:33Z,2020-03-27T09:20:33Z,4240785,NCT04310865,COVID-19,covid-19,Drug|Drug|Other,Yinhu Qingwen Granula|Yin Hu Qing Wen Granula(low does)|standard medical treatment,"Yinhu Qingwen Granula is a kind of herbal granula made from ""Yinhu Qingwen Decoction"", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.",3,|||,Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University,Wuhan|Wuhan|Wuhan|Wuhan,Hubei|Hubei|Hubei|Hubei,430071|430071|430071|430200,China|China|China|China,4
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-09,NA,NA,2020-03-14,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 8, 2020",Actual,2020-03-08,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:20:56Z,2020-03-27T09:20:56Z,4240902,NCT04310228,COVID-19,covid-19,Drug|Drug|Drug,Favipiravir Combined With Tocilizumab|Favipiravir|Tocilizumab,"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",3,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Anhui Medical University Affiliated First Hospital|Guiqiang Wang|Peking University First Hospital|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology|Ezhou Central Hospital|Huoshenshan Hospital of Wuhan|Jinyintan Hospital of Wuhan|Tongji Hospital of Huazhong University of Science and Technology|West Hospital Union Hospital Huazhong University of Science and Technology|Wuhan Pulmonary Hospital|Zhongnan Hospital of Wuhan University,Hefei|Beijing|Beijing|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan,Anhui|Beijing|Beijing|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei,230022|100034|100034|430000|430000|430000|430000|430000|430000|430000|430000,China|China|China|China|China|China|China|China|China|China|China,11
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-10,NA,NA,2020-03-14,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 19, 2020",Anticipated,2020-03-19,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"April 19, 2020",Anticipated,2020-04-19,NA,Observational,NA,,Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life,Acute Respiratory Failure and Continuous Positive Airway Pressure Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: a Real Life Evaluation,Not yet recruiting,NA,NA,50,Anticipated,University of Milan,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-27T09:21:29Z,2020-03-27T09:21:29Z,4241027,NCT04307459,Coronavirus Infections,coronavirus infections,Other,standard operating procedures,"standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.",1,,Luigi Sacco University Hospital,Milan,Lombardia,20157,Italy,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-08,NA,NA,2020-03-16,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-17,Actual,"February 20, 2020",Actual,2020-02-20,March 2020,2020-03-31,"June 20, 2020",Anticipated,2020-06-20,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,TACOS,,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19,Recruiting,NA,NA,120,Anticipated,Tongji Hospital,,NA,3,NA,FALSE,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:21:34Z,2020-03-27T09:21:34Z,4241041,NCT04306705,Covid-19,covid-19,Drug|Other|Procedure,Tocilizumab|Standard of care|Continuous renal replacement therapy,"Administered as an intravenous infusion.|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.|Catheter insertion site is femoral vein.",3,Recruiting,Tongji Hospital,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-01,NA,NA,2020-03-14,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 2, 2020",Actual,2020-03-02,January 2020,2020-01-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Observational,CTOROTSADTOC,,Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.,Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province,Recruiting,NA,NA,340,Anticipated,"Jiangsu Famous Medical Technology Co., Ltd.",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,All researchers in this study,2020-03-27T09:21:35Z,2020-03-27T09:21:35Z,4241047,NCT04306497,COVID-19,covid-19,Drug,TCM prescriptions,"TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.",1,Recruiting,Huai'an fourth people's Hospital,Huaian,Jiangsu,210029,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-08,NA,NA,2020-03-16,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-17,Actual,"March 8, 2020",Actual,2020-03-08,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 31, 2020",Anticipated,2020-05-31,NA,Observational,NA,,Social Media Use During COVID-19,Getting it Right: Towards Responsible Social Media Use During a Pandemic,Recruiting,NA,NA,5000,Anticipated,Yale-NUS College,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2020-03-27T09:21:41Z,2020-03-27T09:21:41Z,4241062,NCT04305574,Coronavirus,coronavirus,Behavioral,Use of social media during COVID-19,Participants' self-reported use of social media to receive and share news about COVID-19,1,Recruiting,Yale-NUS College,Singapore,,138527,Singapore,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:21:49Z,2020-03-27T09:21:49Z,4241090,NCT04304313,COVID-19,covid-19,Drug,Sildenafil citrate tablets,0.1g/day for 14 days,1,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-25,NA,NA,2020-02-25,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-27,Actual,"February 23, 2020",Anticipated,2020-02-23,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study",Not yet recruiting,NA,Phase 4,520,Anticipated,Beijing YouAn Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-09T09:10:50Z,2020-03-09T09:10:50Z,3955471,NCT04286503,Novel Coronavirus Infectious Disease (COVID-19),novel coronavirus infectious disease (covid-19),Drug|Drug|Drug,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,3,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 05, 2020",2020-02-20,NA,NA,2020-02-21,2020-02-21,2020-02-24,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-24,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,A New Screening Strategy for 2019 Novel Coronavirus Infection,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,NA,N/A,230,Anticipated,Affiliated Hospital to Academy of Military Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-06T05:30:36Z,2020-03-06T05:30:36Z,3840560,NCT04281693,Novel Coronavirus Infection Pneumonia,novel coronavirus infection pneumonia,Diagnostic Test|Diagnostic Test,Standard screening strategy|New screening strategy,The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.,2,,the Fifth Medical Center of Chinese PLA General Hospital,Beijing,Beijing,100071,China,1
"ClinicalTrials.gov processed this data on March 16, 2020",2020-02-26,NA,NA,2020-03-04,2020-03-04,2020-03-06,Actual,NA,NA,NA,NA,NA,NA,2020-03-04,2020-03-06,Actual,"March 7, 2020",Anticipated,2020-03-07,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,,Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia,Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia,Not yet recruiting,NA,NA,120,Anticipated,Tongji Hospital,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-17T09:05:42Z,2020-03-17T09:05:42Z,4109834,NCT04298814,COVID-19,covid-19,Other,severe covid-19 pneumonia with ET,severe covid-19 pneumonia undergoing endotracheal intubation,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 27, 2020",2020-02-11,NA,NA,2020-02-14,2020-02-13,2020-02-17,Actual,NA,NA,NA,NA,NA,NA,2020-02-14,2020-02-17,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,,Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children,A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children,Not yet recruiting,NA,NA,500,Anticipated,Beijing Children's Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Serum
    ",NA,NA,NA,Undecided,NA,2020-02-27T20:35:40Z,2020-02-27T20:35:40Z,3660750,NCT04270383,2019-nCoV,2019-ncov,NA,NA,NA,NA,,"Beijing Children's Hospital,",Beijing,,,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-03-01,NA,NA,2020-03-13,2020-03-01,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"March 13, 2020",Actual,2020-03-13,"March 13, 2020",Actual,2020-03-13,NA,Observational,NA,,Prognostic Factors of Patients With COVID-19,Prognostic Factors of Patients With COVID-19,Completed,NA,NA,201,Actual,Chongqing Medical University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-27T09:22:21Z,2020-03-27T09:22:21Z,4241233,NCT04292964,SARS-CoV-2,sars-cov-2,NA,NA,NA,NA,,The First Affiliated Hospital of Chongqing Medical University,Chongqing,,,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-27,NA,NA,2020-03-14,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,550,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:22:29Z,2020-03-27T09:22:29Z,4241259,NCT04291053,COVID-19,covid-19,Drug,Huaier Granule,standard treatment + Huaier Granule 20g po tid for 2weeks,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-13,NA,NA,2020-03-15,2020-02-20,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 21, 2020",Actual,2020-02-21,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,,Study for Novel Coronavirus Pneumonia (NCP),Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP),Recruiting,NA,NA,2000,Anticipated,"Wuhan Union Hospital, China",,NA,NA,NA,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:22:51Z,2020-03-27T09:22:51Z,4241353,NCT04283396,Novel Coronavirus Pneumonia,novel coronavirus pneumonia,Combination Product,systemic treatment,"Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin",1,Recruiting,Union hospital,Wuhan,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-19,NA,NA,2020-03-15,2020-02-19,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 27, 2020",Actual,2020-02-27,March 2020,2020-03-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,China Academy of Chinese Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:23:03Z,2020-03-27T09:23:03Z,4241397,NCT04278963,CoVID-19,covid-19,Drug|Drug|Other|Other,YinHu QingWen Decoction|YinHu QingWen Decoction(low dose)|Chinese medicine treatment|standard western medicine treatment,"YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.",4,||,Jingzhou Hospital of Traditional Chinese Medicine|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University|Xiangyang Hospital of Traditional Chinese Medicine,Jingzhou|Wuhan|Xiangyang,Hubei|Hubei|Hubei,434000|430200|441000,China|China|China,3
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-08,NA,NA,2020-03-13,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 17, 2020",Anticipated,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients,Not yet recruiting,NA,N/A,10,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-27T09:23:44Z,2020-03-27T09:23:44Z,4241554,NCT04264858,2019-nCoV,2019-ncov,Drug|Drug,Immunoglobulin of cured patients|Î³-Globulin,"0.2g/kg, ivdrip, once a day, for 3 days|0.2g/kg, ivdrip, once a day, for 3 days",2,,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430022,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:23:46Z,2020-03-27T09:23:46Z,4241563,NCT04263402,2019-nCoV Severe Pneumonia,2019-ncov severe pneumonia,Drug|Drug,Methylprednisolone|Methylprednisolone,"Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:23:50Z,2020-03-27T09:23:50Z,4241571,NCT04261270,2019-nCoV Pneumonia,2019-ncov pneumonia,Drug|Drug|Drug,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,"ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|75mg ,once a day",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-27T09:24:05Z,2020-03-27T09:24:05Z,4241622,NCT04254874,2019-nCoV,2019-ncov,Drug|Drug,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,"0.2g once, 3 times a day,two weeks|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-Î±-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
"ClinicalTrials.gov processed this data on March 26, 2020",2020-01-30,NA,NA,2020-03-13,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"February 5, 2020",Anticipated,2020-02-05,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study",Withdrawn,NA,N/A,0,Actual,The Second Hospital of Nanjing Medical University,,2,NA,Follow new disciplines on disease control from government,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-27T09:24:12Z,2020-03-27T09:24:12Z,4241641,NCT04251767,COVID-19 Complicated With Refractory Intestinal Infections,covid-19 complicated with refractory intestinal infections,Other|Other,washed microbiota transplantation|placebo,"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.
Dose and frequency: 5u, once.|Placebo (edible suspension of the same color as the washed microbiota suspensionï¼Œ5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
Dose and frequency: 5u, once.",2,,"Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University",Nanjing,Jiangsu,210011,China,1
"ClinicalTrials.gov processed this data on March 25, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-26T09:20:40Z,2020-03-26T09:20:40Z,4225933,NCT04308317,"Corona Virus Disease 2019,COVID-19","corona virus disease 2019,covid-19",Drug,Tetrandrine,Tetrandrine 60mg QD for 1week,1,,Tetrandrine Tablets,Jinhua,Zhejiang,321000,China,1
"ClinicalTrials.gov processed this data on March 20, 2020",2020-03-10,NA,NA,2020-03-12,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-12,2020-03-13,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,Asan Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-23T08:53:53Z,2020-03-23T08:53:53Z,4191420,NCT04307693,COVID-19,covid-19,Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate,Lopinavir / Ritonavir tablet|Hydroxychloroquine sulfate tablet,2,Recruiting,"Asan Medical Center, University of Ulsan College of Medicine",Seoul,,138-736,"Korea, Republic of",1
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-03T05:07:12Z,2020-03-03T05:07:12Z,3751045,NCT04280588,Coronavirus Disease (COVID-19),coronavirus disease (covid-19),Drug,Fingolimod 0.5 mg,"Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days",1,Recruiting,Wan-Jin Chen,Fuzhou,,,China,1
"ClinicalTrials.gov processed this data on March 18, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-19T09:19:21Z,2020-03-19T09:19:21Z,4136453,NCT04299724,Treat and Prevent Covid-19 Infection,treat and prevent covid-19 infection,Biological,Pathogen-specific aAPC,The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.,1,Recruiting,Shenzhen Geno-immune Medical Institute,Shenzhen,Guangdong,518000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-24,NA,NA,2020-03-15,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus,Withdrawn,NA,N/A,0,Actual,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,"Patients were transferred to designated hospitals for treatment as needed, the clinical trials
    cannot be conducted.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-28T09:20:25Z,2020-03-28T09:20:25Z,4256375,NCT04293692,COVID-19,covid-19,Biological|Other,UC-MSCs|Placebo,"0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7",2,,Puren Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei,430081,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-19,NA,NA,2020-02-24,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-02-24,2020-02-26,Actual,"February 26, 2020",Anticipated,2020-02-26,February 2020,2020-02-29,"September 15, 2020",Anticipated,2020-09-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,NA,,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,120,Anticipated,"Tasly Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share,2020-03-08T05:19:27Z,2020-03-08T05:19:27Z,3909827,NCT04285190,Coronavirus Disease 2019,coronavirus disease 2019,Drug,T89,"The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-14,2020-03-14,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-18,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,February 2021,Anticipated,2021-02-28,October 2020,Anticipated,2020-10-31,NA,Observational,SOTSPC,,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,NA,NA,30,Anticipated,Henan Provincial People's Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-28T09:19:24Z,2020-03-28T09:19:24Z,4256129,NCT04312100,Coronavirus Disease-2019,coronavirus disease-2019,Other,oxygen treatment,different kinds of oxygen treatments will be given to patients according to their state of illness,1,Recruiting,Henan Provincial People's Hospital,Zhengzhou,Henan,450000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-18,Actual,"January 1, 2020",Actual,2020-01-01,March 2020,2020-03-31,"March 18, 2020",Anticipated,2020-03-18,"March 15, 2020",Anticipated,2020-03-15,NA,Observational,NA,,Myocardial Damage in COVID-19,Retrospective Study of Myocardial Damage in COVID-19,Enrolling by invitation,NA,NA,500,Anticipated,"Wuhan Union Hospital, China",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-28T09:19:10Z,2020-03-28T09:19:10Z,4256087,NCT04312464,COVID-19,covid-19,Other,non,no intervention,1,,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430022,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-15,NA,NA,2020-03-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Not yet recruiting,NA,Phase 2,460,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-28T09:19:19Z,2020-03-28T09:19:19Z,4256109,NCT04312243,Coronavirus Infections,coronavirus infections,Drug,Inhaled nitric oxide gas,"Observational group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Observational,NA,,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,Not yet recruiting,NA,NA,300,Anticipated,Universita di Verona,,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Nasopharyngeal swabs
    ",NA,NA,NA,NA,NA,2020-03-30T08:56:18Z,2020-03-30T08:56:18Z,4282661,NCT04324866,Coronavirus Infection,coronavirus infection,Diagnostic Test,Nasopharyngeal swab,Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Convalescent Plasma to Limit Coronavirus Associated Complications,"Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19",Not yet recruiting,NA,Phase 2,20,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:55:53Z,2020-03-30T08:55:53Z,4282565,NCT04325672,Coronavirus,coronavirus,Biological,Convalescent Plasma,Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.,1,,Mayo Clinic in Rochester,Rochester,Minnesota,55905,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 30, 2020",Anticipated,2020-03-30,March 2020,2020-03-31,"May 8, 2020",Anticipated,2020-05-08,"April 10, 2020",Anticipated,2020-04-10,NA,Observational,CORONADO,,"""Coronavirus SARS-CoV2 and Diabetes Outcomes""","""Coronavirus SARS-CoV2 and Diabetes Outcomes""",Not yet recruiting,NA,NA,300,Anticipated,Nantes University Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:56:22Z,2020-03-30T08:56:22Z,4282677,NCT04324736,Coronavirus,coronavirus,Other,no interventional study,no interventional study,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 26, 2020",Anticipated,2020-03-26,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 26, 2021",Anticipated,2021-03-26,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Not yet recruiting,NA,Phase 2/Phase 3,180,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-30T08:56:43Z,2020-03-30T08:56:43Z,4282757,NCT04324073,Corona Virus Infection,corona virus infection,Drug,Sarilumab,(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1,1,,NECKER Hospital,Paris,,75005,France,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"February 28, 2023",Anticipated,2023-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,CORSER,,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples,Recruiting,NA,N/A,1000,Anticipated,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:55:53Z,2020-03-30T08:55:53Z,4282571,NCT04325646,COVID-19,covid-19,Other,Human Biological samples,Blood samples for serological tests,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,CHU Amiens-Picardie|CHU FranÃ§ois Mitterand|CHU Limoges|HÃ´pital de la Croix Rousse|HÃ´pitaux de Brabois|CHR OrlÃ©ans|Institut Pasteur|CHU Poitiers|HÃ´pital Pontchaillou|CHU Saint-Etienne|CH de Tourcoing|HÃ´pital Bretonneau,Amiens|Dijon|Limoges|Lyon|Nancy|OrlÃ©ans|Paris|Poitiers|Rennes|Saint-Ã‰tienne|Tourcoing|Tours,|||||||||||,||||||75015|||||,France|France|France|France|France|France|France|France|France|France|France|France,12
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 27, 2021",Anticipated,2021-06-27,"April 27, 2021",Anticipated,2021-04-27,NA,Interventional,ENACOVID,,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Not yet recruiting,NA,Phase 3,584,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:55:54Z,2020-03-30T08:55:54Z,4282572,NCT04325633,COVID-19,covid-19,Drug|Drug,1: Naproxen|2: Standard of care,Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)|Standard of care,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 26, 2020",Anticipated,2020-03-26,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 26, 2021",Anticipated,2021-03-26,NA,Observational,CORIMUNO-19,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Not yet recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-30T08:56:44Z,2020-03-30T08:56:44Z,4282759,NCT04324047,Corona Virus Infection,corona virus infection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"June 23, 2021",Anticipated,2021-06-23,"March 23, 2021",Anticipated,2021-03-23,30 Days,Observational [Patient Registry],CAPACITY-COVID,,Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY,Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY,Recruiting,NA,NA,1000,Anticipated,UMC Utrecht,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:56:01Z,2020-03-30T08:56:01Z,4282596,NCT04325412,COVID-19; Cardiovascular Diseases,covid-19; cardiovascular diseases,NA,NA,NA,NA,Recruiting,University Medical Center Utrecht,Utrecht,,3584 CX,Netherlands,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers",Not yet recruiting,NA,Phase 1/Phase 2,510,Anticipated,University of Oxford,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:56:27Z,2020-03-30T08:56:27Z,4282694,NCT04324606,Coronavirus,coronavirus,Biological|Other,ChAdOx1 nCoV-19|Saline Placebo,5x10^10vp of ChAdOx1 nCoV-19|Saline injection delivered intramuscularly,2,|||,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust|Imperial College Healthcare NHS Trust|CCVTM, University of Oxford, Churchill Hospital|John Radcliffe Hospital",Southampton|London|Oxford|Oxford,Hampshire|||,SO16 6YD|W2 1NY|OX3 7LE|OX3 9DU,United Kingdom|United Kingdom|United Kingdom|United Kingdom,4
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Not yet recruiting,NA,Phase 2/Phase 3,54,Anticipated,Swedish Orphan Biovitrum,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:45Z,2020-03-30T08:56:45Z,4282761,NCT04324021,SARS-CoV-2,sars-cov-2,Biological|Biological,Emapalumab|Anakinra,I.v infusion every third day|Daily i.v infusion,2,|||,"ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta IntensitÃ  di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani",Brescia|Milano|Parma|Roma,|||,|||,Italy|Italy|Italy|Italy,4
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"November 9, 2021",Anticipated,2021-11-09,"October 5, 2020",Anticipated,2020-10-05,1 Month,Observational [Patient Registry],EC-COVID-PCS,,Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.,EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.,Not yet recruiting,NA,NA,3000,Anticipated,Mario Negri Institute for Pharmacological Research,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:50Z,2020-03-30T08:56:50Z,4282786,NCT04323878,Early CPAP Ventilation in COVID-19 Patients,early cpap ventilation in covid-19 patients,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,CYCOV_ECMO,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Not yet recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:29Z,2020-03-30T08:56:29Z,4282700,NCT04324528,Coronavirus,coronavirus,Device|Device,vv-ECMO + cytokine adsorption (Cytosorb adsorber)|vv-ECMO only (no cytokine adsorption),in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)|COVID-19-diseased treated with vv-ECMO,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-27,Estimate,"March 20, 2020",Actual,2020-03-20,March 2020,2020-03-31,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2024",Anticipated,2024-03-31,12 Months,Observational [Patient Registry],PRIORITY,,PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),PRIORITY (Pregnancy Coronavirus Outcomes Registry),Recruiting,NA,NA,1000,Anticipated,"University of California, San Francisco",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:51Z,2020-03-30T08:56:51Z,4282793,NCT04323839,Coronavirus,coronavirus,Other|Other,Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19,This is an observational study with no intervention|This is an observational study with no intervention,2,Recruiting,"University of California, San Francisco",San Francisco,California,94143,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,DEXA-COVID19,,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Not yet recruiting,NA,Phase 4,200,Anticipated,Dr. Negrin University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:12Z,2020-03-30T08:56:12Z,4282641,NCT04325061,Acute Respiratory Distress Syndrome Caused by COVID-19 Infection,acute respiratory distress syndrome caused by covid-19 infection,Drug,Dexamethasone,"Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization",1,,Hospital Universitario Dr. Negrin,Las Palmas de Gran Canaria,,35010,Spain,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",Not yet recruiting,NA,Phase 2,150,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2020-03-30T08:56:52Z,2020-03-30T08:56:52Z,4282797,NCT04323800,Coronavirus,coronavirus,Biological|Biological,Anti- SARS-CoV-2 Plasma|SARS-CoV-2 non-immune Plasma,SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody >1:64)|Standard plasma collected prior to December 2019,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,2 Months,Observational [Patient Registry],NA,,Clinical Evaluation of Cordio Application in Adult COVID19 Virus Positive Patients,Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID19,Not yet recruiting,NA,NA,5000,Anticipated,Cordio Medical,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:13Z,2020-03-30T08:56:13Z,4282642,NCT04325048,Coronavirus Infection,coronavirus infection,Device,Cordio App,Adult patients positive to COVID19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,VIRUS,,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary),Recruiting,NA,NA,50000,Anticipated,Mayo Clinic,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:52Z,2020-03-30T08:56:52Z,4282799,NCT04323787,Coronavirus,coronavirus,Other,observational,No Intervention,1,Recruiting|Recruiting|Recruiting,Mayo Clinic in Arizona|Mayo Clinic in Florida|Rahul Kashyap,Scottsdale|Jacksonville|Rochester,Arizona|Florida|Minnesota,85259|32224|55905,United States|United States|United States,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:14Z,2020-03-30T08:56:14Z,4282647,NCT04324996,COVID-19,covid-19,Biological,"NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.,1,Recruiting,Chongqing Public Health Medical Center,Chongqing,,,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 6, 2020",Actual,2020-03-06,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,DAS181 for COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Recruiting,NA,N/A,4,Anticipated,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:30Z,2020-03-30T08:56:30Z,4282709,NCT04324489,COVID-19,covid-19,Drug,DAS181,"Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.",1,Recruiting,Renmin Hospital of Wuhan University,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-27,Estimate,NA,NA,NA,March 2020,2020-03-31,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection,Available,NA,NA,NA,NA,Gilead Sciences,,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:56:53Z,2020-03-30T08:56:53Z,4282801,NCT04323761,SARS-CoV2 Infection,sars-cov2 infection,Drug,Remdesivir,Intravenous infusion administered over a 30 to 120 minute period,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACT COVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Not yet recruiting,NA,Phase 3,1500,Anticipated,Population Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:56:31Z,2020-03-30T08:56:31Z,4282711,NCT04324463,Coronavirus,coronavirus,Drug|Drug,Azithromycin|Chloroquine,oral medication|oral medication,2,,Hamilton Health Sciences,Hamilton,Ontario,L8L2X2,Canada,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,CovidSurg,,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Not yet recruiting,NA,NA,1000,Anticipated,University of Birmingham,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be available to other researchers,2020-03-30T08:56:57Z,2020-03-30T08:56:57Z,4282816,NCT04323644,COVID-19,covid-19,Procedure,Surgery,Emergency or elective surgery,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Recruiting,NA,Phase 2,440,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-03-30T08:57:01Z,2020-03-30T08:57:01Z,4282836,NCT04323527,SARS-CoV Infection,sars-cov infection,Drug,Chloroquine diphosphate,150mg chloroquine diphosphate tablets.,1,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Not yet recruiting,NA,Early Phase 1,1116,Anticipated,Rambam Health Care Campus,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:56:57Z,2020-03-30T08:56:57Z,4282819,NCT04323631,COVID-19,covid-19,Drug|Other,Hydroxychloroquine|The control group will not receive hydroxychloroquine,Oral|The control group will not receive hydroxychloroquine,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,MP-C19,,Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Recruiting,NA,Phase 2/Phase 3,104,Anticipated,University of Trieste,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2020-03-30T08:56:59Z,2020-03-30T08:56:59Z,4282823,NCT04323592,Coronavirus Infections,coronavirus infections,Drug|Other,Methylprednisolone|standard care,"Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description|usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins",2,Recruiting,Marco Confalonieri,Trieste,TS,34149,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,N/A,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:57:01Z,2020-03-30T08:57:01Z,4282838,NCT04323514,Hospitalized Patients With Covid-19 Pneumonia,hospitalized patients with covid-19 pneumonia,Dietary Supplement,Vitamin C,10 gr of vitamin C intravenously in addition to conventional therapy.,1,Recruiting,A.R.N.A.S. Civico - Di Cristina - Benfratelli,Palermo,,90127,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Estimate,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,DISPOSE,,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Not yet recruiting,NA,N/A,600,Anticipated,International Psychoanalytic University Berlin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:56:40Z,2020-03-30T08:56:40Z,4282745,NCT04324190,COVID-19,covid-19,Behavioral|Behavioral,Guided online support program|WHO recommendations (waiting condition),"Guided online support program consisting of several modules; Module ""General information ..."" is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)|During the waiting period, a german translation of the WHO recommendations ""Coping with stress during the 2019-nCoV outbreak"" is provided",2,,Selfapy GmbH,Berlin,,10435,Germany,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"May 19, 2020",Anticipated,2020-05-19,"May 19, 2020",Anticipated,2020-05-19,NA,Observational,SISCO,,An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection,An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Recruiting,NA,NA,50,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:57:45Z,2020-03-30T08:57:45Z,4283027,NCT04322188,Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection,severe acute respiratory syndrome (ards) secondary to sars-cov-2 infection,NA,NA,NA,NA,Recruiting,ASST - Papa Giovanni XXIII,Bergamo,,24127,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus,"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients",Not yet recruiting,NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:57:47Z,2020-03-30T08:57:47Z,4283036,NCT04322123,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,Hydroxychloroquine 400 mg BID|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day,2,|||||||||||||||||||||||||||||||,Hospital Geral ClÃ©riston Andrade|Hospital Ana Nery - HAN/SESAB|HHospital SAMUR|Hospital Geral de VitÃ³ria da Conquista|Hospital de BrasÃ­lia|Instituto de Cardiologia do Distrito Federal|Hospital Maternidade SÃ£o JosÃ© - UNESC - FundaÃ§Ã£o Social Rural de Colatina|Hospital Vila da Serra|Santa Casa de MisericÃ³rdia de SÃ£o JoÃ£o Del Rei|AssociaÃ§Ã£o EvangÃ©lica Beneficente de Londrina - Hospital EvangÃ©lico de Londrina|Instituto Estadual do CÃ©rebro Paulo Niemeyer|Hospital Geral de Caxias do Sul|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o Francisco - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o JosÃ©|Hospital BaÃ­a Sul - BaÃ­a Sul Medical Center|Hospital Nereu Ramos|Centro Hospitalar Unimed|Hospital de Amor - Unidade Barretos (FundaÃ§Ã£o PIO XII)|Faculdade de Medicina de SÃ£o JosÃ© do Rio Preto|AC Camargo Cancer Center - FundaÃ§Ã£o Antonio Prudente|Casa de SaÃºde Santa Marcelina|Hospital Albert Einstein|Hospital BeneficÃªncia Portuguesa - Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia|Hospital BP Mirante - Real e BenemÃ©rita|Hospital da Luz - Amico SaÃºde LTDA|Hospital das ClÃ­nicas da FMUSP|Hospital do Servidor PÃºblico Estadual - HSPE - IAMSPE|Hospital SÃ£o Paulo - UNIFESP|Hospital SÃ­rio-LibanÃªs|Hospital SEPACO|Hospital das ClÃ­nicas da Faculdade de Medicina da USP - RibeirÃ£o Preto,Feira De Santana|Salvador|VitÃ³ria Da Conquista|VitÃ³ria Da Conquista|Brasilia|BrasÃ­lia|Colatina|Nova Lima|SÃ£o JoÃ£o Del Rei|Londrina|Rio De Janeiro|Caxias do Sul|Porto Alegre|Porto Alegre|Criciuma|FlorianÃ³polis|FlorianÃ³polis|Joinville|Barretos|SÃ£o JosÃ© do Rio Preto|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|RibeirÃ£o Preto,BA|BA|BA|BA|DF|DF|ES|MG|MG|PR|RJ|RS|RS|RS|SC|SC|Sc|SC|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|S|SÃ£o Paulo,|||||||||||||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,32
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"May 10, 2020",Anticipated,2020-05-10,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Not yet recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:57:07Z,2020-03-30T08:57:07Z,4282860,NCT04323345,COVID-19,covid-19,Dietary Supplement|Other,Natural Honey|Standard Care,Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.,2,,Mahmoud Tantawy,Cairo,,,Egypt,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,July 2021,Anticipated,2021-07-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Not yet recruiting,NA,Phase 2,1000,Anticipated,Nova Scotia Health Authority,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:57:52Z,2020-03-30T08:57:52Z,4283046,NCT04321993,COVID-19,covid-19,Drug|Drug|Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate|Baricitinib (janus kinase inhibitor)|Sarilumab (anti-IL-6 receptor),"Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth, every 12 hours for 10 days|Hydroxychloroquine sulfate sulfate tablet 200 mg 2 tablets by mouth, every 12 hours for 10 days|Baricitinib 2 mg po daily for 10 days|Sarilumab 200mg subcutaneous injection once",4,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-08,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,Traditional Chinese Medicine for Severe COVID-19,A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19,Not yet recruiting,NA,Phase 3,50,Anticipated,Xiyuan Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-30T08:57:07Z,2020-03-30T08:57:07Z,4282861,NCT04323332,COVID-19,covid-19,Drug,Traditional Chinese Medicine Prescription,Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.,1,,Hao Li,Beijing,Beijing,100091,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-26,Actual,"January 1, 1998",Actual,1998-01-01,March 2020,2020-03-31,"March 31, 2020",Anticipated,2020-03-31,"May 31, 2016",Actual,2016-05-31,NA,Observational,NA,,"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.","Active, not recruiting",NA,NA,1302508,Actual,"University College, London",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:57:26Z,2020-03-30T08:57:26Z,4282940,NCT04322786,"Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","covid-19, coronavirus, angiotensin converting enzyme inhibitors, influenza, electronic health records, epidemiology, comorbidity, incidence, united kingdom",Drug,ACE inhibitor,Any prescription of ACE inhibitor,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Not yet recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:57:54Z,2020-03-30T08:57:54Z,4283053,NCT04321928,SARS-CoV-2,sars-cov-2,Behavioral|Behavioral,Personalized health education|General health education,"Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Not yet recruiting,NA,Phase 2,200,Anticipated,Frederiksberg University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-03-30T08:57:26Z,2020-03-30T08:57:26Z,4282941,NCT04322773,Corona Virus Disease,corona virus disease,Drug|Drug|Drug|Other,RoActemra iv|RoActemra sc|Kevzara sc|Standard medical care,single dose treatment with tocilizumab 400 mg intravenously|single dose treatment with tocilizumab 2 x 162 mg subcutaneously|single dose treatment with sarilumab 1 x 200 mg subcutaneously|management as usual,4,,Bispebjerg-Frederiksberg Hospital,Copenhagen,,2000,Denmark,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"October 30, 2020",Anticipated,2020-10-30,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,ONSCOVID19,,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Not yet recruiting,NA,Phase 4,30,Anticipated,King Saud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2020-03-30T08:57:10Z,2020-03-30T08:57:10Z,4282874,NCT04323228,COVID-19,covid-19,Dietary Supplement|Dietary Supplement,"oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|isocaloric/isonutrigenous ONS","the intervention group will receive a commercially available anti-inflammatory/antioxidant ONS, which will be given to patients with COVID-19 in the morning 3 hours after breakfast.|The placebo group will receive an isocaloric/isonutrigenous ONS at the same time in the same shape/size/color of the cans.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,1 Year,Observational [Patient Registry],BEAT19,,"Behavior, Environment And Treatments for Covid-19",A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19),Recruiting,NA,NA,100000,Anticipated,xCures,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,De-identified datasets will be made available to qualified researchers in accordance with the study protocol.,2020-03-30T08:57:58Z,2020-03-30T08:57:58Z,4283067,NCT04321811,Coronavirus,coronavirus,Other,"Observation of patients with known, suspected, or at risk for COVID-19 infection",Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.,1,Recruiting,xCures,San Francisco,California,94022,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-26,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T08:57:29Z,2020-03-30T08:57:29Z,4282957,NCT04322682,Corona Virus Infection,corona virus infection,Drug|Drug,Colchicine|Placebo oral tablet,"Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.",2,Recruiting,Montreal Heart Institute,Montreal,Quebec,H1T 1C8,Canada,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,"March 26, 2020",Anticipated,2020-03-26,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Not yet recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-03-30T08:58:05Z,2020-03-30T08:58:05Z,4283094,NCT04321616,SARS-CoV Infection,sars-cov infection,Drug|Drug|Other,Hydroxychloroquine|Remdesivir|(Standard of Care) SoC,Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 600 mg x 2 loading dose followed by 200 mg x 3 every day for 10 days.|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization up to a in 9 days10 days total course. A loading dose of 200 mg at inclusion will be given.|The standard of care will be supplied to all patients not receiving a drug intervention.,3,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Colchicine Efficacy in COVID-19 Pneumonia,COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA,Not yet recruiting,NA,Phase 2,100,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from June 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-03-30T08:57:33Z,2020-03-30T08:57:33Z,4282968,NCT04322565,Coronavirus Infections,coronavirus infections,Drug,Colchicine,Cochicine 1mg/day,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,,Pandemic Response Network,Pandemic Response Network: Duke Community Health Watch,Not yet recruiting,NA,NA,20000,Anticipated,Duke University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:58:30Z,2020-03-30T08:58:30Z,4283232,NCT04320862,COVID-19,covid-19,NA,NA,NA,NA,,Duke University Medical Center,Durham,North Carolina,27713,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 24, 2020",Actual,2020-03-24,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,B-DT-COV2,,Biomarkers for Identification of SARS-COV-2 Infection,Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection,Recruiting,NA,NA,110,Anticipated,University of Catanzaro,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:57:34Z,2020-03-30T08:57:34Z,4282975,NCT04322513,Coronavirus,coronavirus,Diagnostic Test,Biomarkers expression,Evaluation in biomarkers expression between 2 groups,1,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,"Active, not recruiting",NA,N/A,49,Anticipated,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2020-03-30T08:58:12Z,2020-03-30T08:58:12Z,4283120,NCT04321421,COVID-19,covid-19,Other,hyperimmune plasma,administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5,1,,Catherine Klersy,Pavia,PV,27100,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 15, 2021",Anticipated,2021-01-15,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,LUSCOVID19,,"Simple, Safe, Same: Lung Ultrasound for COVID-19","Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method",Not yet recruiting,NA,NA,100,Anticipated,Catholic University of the Sacred Heart,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:57:35Z,2020-03-30T08:57:35Z,4282977,NCT04322487,Coronavirus,coronavirus,Diagnostic Test,Lung ultrasound,"A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.",1,||||||||,"Bresciamed|Pulmonary Medicine Unit, Lodi General Hospital|118 USL Nordovest Toscana|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento|Emergency Medicine Unit, General Hospital",Brescia|Lodi|Lucca|Lucca|Pavia|Roma|Roma|Trento|Voghera,||||||||,|||||00168|00168||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,9
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"March 20, 2030",Anticipated,2030-03-20,"March 28, 2022",Anticipated,2022-03-28,NA,Observational,NA,,Risk Factors for Community- and Workplace Transmission of COVID-19,Risk Factors for Community- and Workplace Transmission of COVID-19,Not yet recruiting,NA,NA,50000,Anticipated,Oslo University Hospital,,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood and upper repiratory samples will be collected from some participants.
    ",NA,NA,NA,No,"European GDPR regulations severely limits IPD, but the study will share data to the largest extent possible within GDPR.",2020-03-30T08:58:35Z,2020-03-30T08:58:35Z,4283247,NCT04320732,Coronavirus,coronavirus,Behavioral,Observation of behavior and COVID-19 infection will be conducted.,"No intervention, only prospective observation of behavior will be conducted by a questionnaire.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Alliance Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Alliance COVID-19 Brasil II - Severely-ill Patients,Not yet recruiting,NA,Phase 3,440,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T08:58:16Z,2020-03-30T08:58:16Z,4283140,NCT04321278,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine + azithromycin|Hydroxychloroquine,"Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.",2,|||||||||||||||||||||,Hospital Ana Nery|Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Eurolatino Natal Pesquisas MÃ©dicas Ltda|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Hospital das ClÃ­nicas da Faculdade de Medicina de RibeirÃ£o Preto da USP - HCFMRP|Santa Casa de Misericordia de Votuporanga|Hospital Israelita Albert Einstein|AMICO Saude LTDA|Associacao Beneficente Siria|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo,Salvador|BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|RibeirÃ£o Preto|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Bahia|Distrito Federal|Espirito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|||||||||,|||||||||||||05652-900||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,22
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"April 3, 2020",Anticipated,2020-04-03,March 2020,2020-03-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Not yet recruiting,NA,Phase 3,330,Anticipated,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).
Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2020-03-30T08:58:39Z,2020-03-30T08:58:39Z,4283258,NCT04320615,COVID-19 Pneumonia,covid-19 pneumonia,Drug|Drug,Tocilizumab (TCZ)|Placebo,Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.|Participants will receive 1 dose of IV placebo matched to TCZ.,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Observational,COVIP,,Outcomes and Prognostic Factors in COVID-19,Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients,Recruiting,NA,NA,4000,Anticipated,"Heinrich-Heine University, Duesseldorf",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:58:17Z,2020-03-30T08:58:17Z,4283142,NCT04321265,COVID-19,covid-19,NA,NA,NA,NA,Recruiting,"Division of Cardiology, Pulmonary Disease and Vascular Medicine",Duesseldorf,,40225,Germany,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T08:57:40Z,2020-03-30T08:57:40Z,4283002,NCT04322344,Coronavirus Infections,coronavirus infections,Drug|Drug,Escin|standard therapy,treatment with escin or escinate sodium|antiviral drugs,2,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,"COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",Recruiting,NA,NA,25,Anticipated,William Beaumont Hospitals,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T08:58:42Z,2020-03-30T08:58:42Z,4283266,NCT04320511,SARS-COV2,sars-cov2,Device,CT-V,"CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan",1,Not yet recruiting|Recruiting,Beaumont Health|Beaumont Hospital - Royal Oak,Royal Oak|Royal Oak,Michigan|Michigan,48073|48073,United States|United States,2
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-22,NA,NA,2020-03-24,2020-03-22,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,3 Months,Observational [Patient Registry],NeuroCOVID19,,Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection,Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection,Recruiting,NA,NA,250,Anticipated,Ictal Group,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:58:43Z,2020-03-30T08:58:43Z,4283272,NCT04320472,COVID-19,covid-19,Other,Follow up,"Follow up up to day 90 (Glasgow outcome scale, functionnal impairments)",1,Recruiting,Centre Hospitalier de Versailles,Le Chesnay,,78150,France,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 9, 2020",Actual,2020-03-09,March 2020,2020-03-31,"May 1, 2020",Anticipated,2020-05-01,"May 1, 2020",Anticipated,2020-05-01,NA,Observational,NA,,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO),Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection,Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples
    ",NA,NA,NA,Undecided,NA,2020-03-30T08:57:42Z,2020-03-30T08:57:42Z,4283013,NCT04322279,Coronavirus,coronavirus,Diagnostic Test|Genetic,Serology|Sequencing,SARS-CoV-2 serology|Whole exome sequencing,2,Recruiting,CIC 1425,Paris,,,France,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-18,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 30, 2020",Anticipated,2020-03-30,March 2020,2020-03-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Not yet recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-03-30T08:58:19Z,2020-03-30T08:58:19Z,4283159,NCT04321174,Coronavirus Infections,coronavirus infections,Drug,Lopinavir/ritonavir,"The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.",1,||,Sunnybrook Hospital|St. Michael's Hospital|Toronto General Hospital,Toronto|Toronto|Toronto,Ontario|Ontario|Ontario,M4N 3M5|M5B 1W8|M5G 2N2,Canada|Canada|Canada,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-16,NA,NA,2020-03-20,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-24,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,"March 16, 2020",Anticipated,2020-03-16,"March 16, 2020",Actual,2020-03-16,NA,Observational,NA,,Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak,Recruiting,NA,NA,400,Anticipated,Assiut University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:59:26Z,2020-03-30T08:59:26Z,4283436,NCT04319315,COVID-19,covid-19,Other,survey,online survey,1,Recruiting,Assiut University Hospitals,Assiut,,71515,Egypt,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Not yet recruiting,NA,Phase 1/Phase 2,180,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-03-30T08:58:22Z,2020-03-30T08:58:22Z,4283169,NCT04321096,Corona Virus Infection,corona virus infection,Drug|Drug,Camostat Mesilate|Placebo oral tablet,Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2|Placebo,2,||,"Department of Infectious Diseases|Department for Infectious Diseases, Aarhus University Hospital|Dept. of Infectious Diseases, Odense University Hospital",Aalborg|Aarhus N|Odense,||,|8200|5000,Denmark|Denmark|Denmark,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,April 2022,Anticipated,2022-04-30,March 2022,Anticipated,2022-03-31,NA,Observational,COVIDSOT,,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Not yet recruiting,NA,NA,50,Anticipated,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      -  Biochemical analysis

        -  Hemogram

        -  Microbiological testing will be made: blood culture, pleural liquid culture, gram stain
           and culture of sputum, detection of pneumococcus and Legionella pneumophila antigen in
           urine, in cases of pneumonia.

        -  Nasopharyngeal swabs
    ",One year after the initiation of the study,Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC),NA,Yes,Planning for the study will be shared with potential sites pertaining to Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) for participation. IPD is not foreseen out of this groups due to the specific characteristics of patients and sites to be candidates for study participation.,2020-03-30T08:59:31Z,2020-03-30T08:59:31Z,4283454,NCT04319172,"Infections, Coronavirus","infections, coronavirus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-21,NA,NA,2020-03-21,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:58:51Z,2020-03-30T08:58:51Z,4283301,NCT04320238,2019 Novel Coronavirus Infection,2019 novel coronavirus infection,Drug|Drug,recombinant human interferon Alpha-1b|thymosin alpha 1,"recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.|thymosin alpha 1 subcutaneous injection 1 time per week.",2,Recruiting,Taihe Hospital,Shiyan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Not yet recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:00:13Z,2020-03-30T09:00:13Z,4283595,NCT04318015,COVID-19,covid-19,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,All treatment will be administered orally.|All placebo will be administered orally,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-26,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia,Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Not yet recruiting,NA,N/A,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2020-03-30T08:58:57Z,2020-03-30T08:58:57Z,4283319,NCT04320056,Coronavirus,coronavirus,Other|Device,Standard administration of oxygen flow|Automated oxygen administration - FreeO2,"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.
In this group the SpO2 was recorded any time with FreeO2 device - recording mode|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,330,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:00:47Z,2020-03-30T09:00:47Z,4283714,NCT04317092,COVID-19 Pneumonia,covid-19 pneumonia,Drug,Tocilizumab Injection,"Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia)|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive)|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza)|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O.|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive)|ASST OVEST MILANESE presidi Legnano - Magenta|Azienda Ospedaliero-Universitaria di Modena|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I)|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II)|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive)|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia)|National Cancer Institute|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva)|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio)|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza)|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione)|Grande Ospedale Metropolitano, Reggio Calabria|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive)|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche)|ASST Sette Laghi (Dipartimento di Medicina Interna)|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze)|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale)|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali)|A.O.U. Integrata di Verona (Dip. Malattie Infettive)|Ospedale Magalini (U.O. Malattie Infettive)",Alessandria|Busto Arsizio|Catania|Catania|Cosenza|Magenta|Modena|Modena|Modena|Modena|Modena|Naples|Naples|Naples|Naples|Pesaro|Pozzuoli|Ravenna|Reggio Calabria|Rimini|Rome|Varese|Varese|Varese|Varese|Verona|Villafranca Di Verona,||||||||||||||||||||||||||,||||||42100|||||80131|80131||||||||||||||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,27
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,"March 20, 2020",Actual,2020-03-20,March 2020,2020-03-31,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Observational,JOCOVID,,Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19,Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19,Recruiting,NA,NA,500,Anticipated,Groupe Hospitalier Pitie-Salpetriere,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:58:58Z,2020-03-30T08:58:58Z,4283327,NCT04320017,COVID-19,covid-19,Diagnostic Test,Electrocardiogram and transthoracic echocardiography,12 derivations electrocardiogram done at baseline transthoracic echocardiography,1,Recruiting,Clinical Investigation Center PitiÃ©-SalpÃªtriÃ¨re,Paris,,75013,France,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,May 2020,Anticipated,2020-05-31,March 2020,2020-03-31,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Not yet recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:00:49Z,2020-03-30T09:00:49Z,4283719,NCT04317040,Severe Coronavirus Disease (COVID-19),severe coronavirus disease (covid-19),Drug|Drug,CD24Fc|Placebo,CD24Fc is given on Day 1.|Placebo is given on Day 1.,2,,"Institute of Human Virology, University of Maryland Baltimore",Baltimore,Maryland,21201,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:59:03Z,2020-03-30T08:59:03Z,4283345,NCT04319900,Novel Coronavirus Pnuemonia,novel coronavirus pnuemonia,Drug|Drug|Drug,favipiravir tablets+chloroquine phosphatetablets tablets|Favipiravir tablets|Placebo,"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).
Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.",3,Recruiting,Beijing Chaoyang hospital,Beijing,Beijing,100020,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-24,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Not yet recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-03-30T08:59:55Z,2020-03-30T08:59:55Z,4283536,NCT04318444,COVID-19,covid-19,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.",2,,Columbia University Irving Medical Center,New York,New York,10032,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 20, 2020",Actual,2020-03-20,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,NA,,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Predictors of Respiratory Failure Requiring ICU Admission Among Hospitalized Patients With SARS-Cov-2 Infection,Recruiting,NA,NA,350,Anticipated,University of Bologna,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Participant from other centers may request to analyze the registry for other purposes upon IRB and study group approval,2020-03-30T09:00:52Z,2020-03-30T09:00:52Z,4283730,NCT04316949,SARS-CoV-2 Pneumonia,sars-cov-2 pneumonia,NA,NA,NA,NA,Recruiting,University of Bologna - Department of Medical and Surgical Sciences,Bologna,,40138,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 12, 2020",Actual,2020-03-12,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,UMODCOVID19,,Mechanisms for Organ Dysfunction in Covid-19,Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19,Recruiting,NA,NA,100,Anticipated,Uppsala University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Plasma, Urine and Sputum
    ",NA,NA,NA,Undecided,IPD may be made available upon reasonable request.,2020-03-30T09:00:55Z,2020-03-30T09:00:55Z,4283736,NCT04316884,COVID-19,covid-19,NA,NA,NA,NA,Recruiting,Uppsala University Hospital,Uppsala,,75185,Sweden,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-18,NA,NA,2020-03-19,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,HOPE,,NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Exploratory Clinical Study to Assess the Efficacy of NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,NA,Phase 1,24,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-03-30T09:01:29Z,2020-03-30T09:01:29Z,4283847,NCT04315987,COVID-19 Pneumonia,covid-19 pneumonia,Biological|Biological,NestCellÂ®|NestCellÂ®,"Phase 1 of the study: 6 patients will receive conventional treatment plus 3 times of 1x10^6 cells /kg body weight of NestCellÂ® intravenously on Day1, Day3 and Day7|Phase 2 of the study: After Safety Monitoring Board evaluation, 18 patients will receive conventional treatment plus the dose and posology of NestCellÂ® recommended by Board.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-25,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,COVILLE,,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Not yet recruiting,NA,N/A,600,Anticipated,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T08:59:55Z,2020-03-30T08:59:55Z,4283538,NCT04318431,Covid19,covid19,Diagnostic Test,Data collection and rhinopharyngeal swab,Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing,1,|||||||||||||||,Cabinet du Dr Belaroussi|Cabinet du Dr Derkx|Cabinet du Dr Coicadan|Cabinet du Dr Corrard|53 Boulevard De La LibertÃ©|157 Avenue du GÃ©nÃ©ral Leclerc|Cabinet du Dr Bodin|Cabinet du Dr Deberdt|Cabinet du Dr Wollner|Cabinet du Dr D'acremont|Cabinet du Dr Romain|Cabinet du Dr Turberg-Romain|Cabinet du Dr Michot|Cabinet du Dr Cohen|Cabinet de PÃ©diatrie des Docteurs Ravilly et Bessa|13 Villa BeausÃ©jour,Boulogne|Champigny-sur-Marne|ChenneviÃ¨res-sur-Marne|Combs-la-Ville|Les Lilas|Maisons-Alfort|Montgeron|Nogent-sur-Marne|Nogent-sur-Marne|Paris|Paris|Paris|Paris|Saint-Maur-des-FossÃ©s|Villejuif|Vincennes,|||||||||||||||,92100|94500|94430|77380|93260|94700|91230|94130|94130|75009|75015|75015|75016|94100|94800|94300,France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France,16
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-24,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 10, 2020",Anticipated,2020-04-10,NA,Observational,CODIV-ACE,,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Not yet recruiting,NA,NA,5000,Anticipated,Neuromed IRCCS,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:59:56Z,2020-03-30T08:59:56Z,4283539,NCT04318418,COVID-19,covid-19,NA,NA,NA,NA,,"IRCCS Neuromed, Department of Epidemiology and Prevention",Pozzilli,,86077,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-23,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T09:01:30Z,2020-03-30T09:01:30Z,4283850,NCT04315948,Corona Virus Infection,corona virus infection,Drug|Drug|Drug|Drug|Other,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine|Standard of care,"The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.|The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the ""a"" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).|IFN-ÃŸ-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 Âµg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).|Standard of care.",5,Recruiting|Recruiting|Recruiting,CHRU Lille|CHU Nantes|APHP - Bichat Claude Bernard,Lille|Nantes|Paris,||,59000|44000|75018,France|France|France,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-18,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Not yet recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-03-30T09:01:33Z,2020-03-30T09:01:33Z,4283856,NCT04315896,COVID-19,covid-19,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,hydroxychloroquine 400mg day for 10 days|Placebo oral tablet,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-17,NA,NA,2020-03-18,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Observational,CovidTox,,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,NA,1000,Anticipated,Groupe Hospitalier Pitie-Salpetriere,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No individual data is available per se. They need to be retrieved from the World Health Organization.,2020-03-30T09:01:46Z,2020-03-30T09:01:46Z,4283908,NCT04314817,Coronavirus,coronavirus,Drug,Any drug used to treat Covid-19,"lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.",1,Recruiting,AP-HP Assistance Publique Hopitaux de Paris,Paris,,,France,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-19,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Observational,COVID-BioB,,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",Recruiting,NA,NA,1000,Anticipated,UniversitÃ  Vita-Salute San Raffaele,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T08:59:57Z,2020-03-30T08:59:57Z,4283544,NCT04318366,Coronavirus Infections,coronavirus infections,Other,Observational Study,Not required,1,Recruiting,UniversitÃ  Vita-Salute San Raffaele,Milano,Mi,20132,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-14,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19,Not yet recruiting,NA,N/A,200,Anticipated,"Centro Studi Internazionali, Italy",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months,Still under development,NA,Yes,Still under development,2020-03-30T09:01:01Z,2020-03-30T09:01:01Z,4283756,NCT04316728,Coronavirus Infections,coronavirus infections,Device,VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test,"VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma",1,,"UnitÃ ' Complesse di cure primarie (UCCP), ASP Catanzaro",Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-17,NA,NA,2020-03-25,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,6 Months,Observational [Patient Registry],COVID19-HCW,,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,NA,400,Anticipated,"University College, London",,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples Nasal and oropharygeal swabs
    ",NA,NA,NA,Yes,Publication of results in open access journals; sharing of results in scientific databases.,2020-03-30T08:59:59Z,2020-03-30T08:59:59Z,4283551,NCT04318314,Coronavirus,coronavirus,Diagnostic Test,COPAN swabbing and blood sample collection,COPAN swabbing of nostrils and/or oropharynx and blood sample collection,1,"Recruiting|Active, not recruiting",Barts Heart Center|Royal Free London NHS Foundation Trust,London|London,|,|,United Kingdom|United Kingdom,2
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-17,NA,NA,2020-03-18,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"August 18, 2020",Anticipated,2020-08-18,"August 16, 2020",Anticipated,2020-08-16,NA,Observational,AI-COVID-Xr,,Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations,Recruiting,NA,NA,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:01:51Z,2020-03-30T09:01:51Z,4283923,NCT04313946,COVID-19,covid-19,Diagnostic Test,Scanning Chest X-rays and performing AI algorithms on images,Chest X-Rays; AI CNNs; Results,1,Recruiting,University of Medicine and Pharmacy Gr T Popa,IaÅŸi,,,Romania,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 3, 2025",Anticipated,2025-03-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 4,202,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T09:01:14Z,2020-03-30T09:01:14Z,4283796,NCT04316377,Corona Virus Infection,corona virus infection,Drug,Hydroxychloroquine Sulfate,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-15,NA,NA,2020-03-20,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-24,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,APICTH,,A Phase I Clinical Trial in 18-60 Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Recruiting,NA,Phase 1,108,Anticipated,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:01:56Z,2020-03-30T09:01:56Z,4283953,NCT04313127,COVID-19,covid-19,Biological,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Intramuscular other name:Ad5-nCoV,1,Recruiting,Hubei Provincial Center for Disease Control and Prevention,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-20,NA,NA,2020-03-21,2020-03-20,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"March 30, 2020",Anticipated,2020-03-30,"March 28, 2020",Anticipated,2020-03-28,NA,Observational,HT-COVID19,,Hypertension in Patients Hospitalized With COVID-19,"Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study","Active, not recruiting",NA,NA,275,Actual,Nanfang Hospital of Southern Medical University,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,None Retained,"
      Blood
    ",NA,NA,NA,Undecided,NA,2020-03-30T09:00:00Z,2020-03-30T09:00:00Z,4283554,NCT04318301,COVID-19,covid-19,NA,NA,NA,NA,,Hankou Hospital,Hankou,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-16,NA,NA,2020-03-22,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19,Not yet recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:01:57Z,2020-03-30T09:01:57Z,4283954,NCT04313023,COVID-19,covid-19,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) PUL-042 Inhalation Solution will be given by nebulization on study days 1, 3, 6, and 10|Sterile normal saline for inhalation",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-17,NA,NA,2020-03-22,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"February 26, 2020",Actual,2020-02-26,March 2020,2020-03-31,"March 8, 2020",Actual,2020-03-08,"February 28, 2020",Actual,2020-02-28,NA,Observational,NA,,Acute Kidney Injury in Patients Hospitalized With COVID-19,"Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study",Completed,NA,NA,287,Actual,Nanfang Hospital of Southern Medical University,,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:01:17Z,2020-03-30T09:01:17Z,4283802,NCT04316299,COVID-19,covid-19,NA,NA,NA,NA,,Hankou Hospital,Wuhan,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-16,NA,NA,2020-03-22,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:01:57Z,2020-03-30T09:01:57Z,4283956,NCT04312997,COVID-19,covid-19,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) given by nebulization on study days 1, 3 and 6|Sterile normal saline for inhalation",2,,Houston Methodist Hospital,Houston,Texas,77030,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Not yet recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:02Z,2020-03-30T09:02:02Z,4283972,NCT04312009,Corona Virus Infection,corona virus infection,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-11,NA,NA,2020-03-25,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"May 12, 2020",Anticipated,2020-05-12,"April 21, 2020",Anticipated,2020-04-21,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis and Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3000,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:13Z,2020-03-30T09:02:13Z,4284015,NCT04308668,Corona Virus Infection,corona virus infection,Drug|Other,Hydroxychloroquine|Placebo,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days",2,Recruiting|Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota|Internet",Minneapolis|Minneapolis|New York,Minnesota|Minnesota|New York,55455|55455|10001,United States|United States|United States,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-14,NA,NA,2020-03-24,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Not yet recruiting,NA,Phase 2,120,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-30T09:02:04Z,2020-03-30T09:02:04Z,4283979,NCT04311697,Corona Virus Infection,corona virus infection,Drug|Drug,Aviptadil by intravenous infusion + maximal intensive care|Normal Saline Infusion + Maximal intensive care,Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.|Maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.,2,|,Research Center|Rambam Health Care Campus,New York|Haifa,New York|,10016|3109601,United States|Israel,2
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Not yet recruiting,NA,Phase 2,516,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:07Z,2020-03-30T09:02:07Z,4283988,NCT04311177,Corona Virus Infection,corona virus infection,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-21,NA,NA,2020-03-19,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"March 3, 2020",Actual,2020-03-03,"February 20, 2020",2020-02-20,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection,"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,45,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T09:03:05Z,2020-03-30T09:03:05Z,4284209,NCT04283461,Corona Virus Infection,corona virus infection,Biological,mRNA-1273,"Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.",1,Not yet recruiting|Recruiting,Emory Children's Center - Pediatric Infectious Diseases|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Decatur|Seattle,Georgia|Washington,30030-1705|98101-1466,United States|United States,2
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-28,NA,NA,2020-03-24,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 6, 2020",Actual,2020-03-06,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Recruiting,NA,Phase 3,400,Anticipated,Gilead Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:45Z,2020-03-30T09:02:45Z,4284137,NCT04292899,COVID-19,covid-19,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of care therapy per local written policies or guidelines,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Kaiser Permanente Los Angeles Medical Center|Hoag Memorial Hospital Presbyterian|Providence St. Johns Medical Center|Stanford Hospital|University of Chicago|Brigham & Women's Hospital and Harvard Medical School|Beth Israel Deaconess Medical Center|Hackensack University Medical Center|Danbury Hospital|New York Presbyterian Hospital/Weill Cornell Medical College|Providence Portland Medical Center|Providence St. Vincent Medical Center|The Miriam Hospital|Baylor University Medical Center|Houston Methodist Hospital|VCU Health Medical Center|Providence Regional Medical Center Everett|Swedish Center for Comprehensive Care|MultiCare Deaconess Hospital|MultiCare Tacoma General Hospital|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|ASST degli Spedali Civili di Brescia - Spedali Civ|ASST di Cremona - Azienda Socio Sanitaria Territor|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Clinic de Barcelona|Hospital Universitario La Paz|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital",Los Angeles|Newport Beach|Santa Monica|Stanford|Chicago|Boston|Boston|Hackensack|Lagrangeville|New York|Portland|Portland|Providence|Dallas|Houston|Richmond|Everett|Seattle|Spokane|Tacoma|Hong Kong|Hong Kong|Hong Kong|Brescia|Cremona|Padova PD|Pavia|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Barcelona|Madrid|Kaohsiung|Taichung|Taipei City,California|California|California|California|Illinois|Massachusetts|Massachusetts|New Jersey|New York|New York|Oregon|Oregon|Rhode Island|Texas|Texas|Virginia|Washington|Washington|Washington|Washington||||||||||||||||||,90027|92658|90404|94305|60637|02115|02215|07601|12540|10065|97213|97225|02906|75246|77030|23298|98201|98104|99204|98405||||25123|26100|35121|27100|41944|02053|04564|119228|169856|308442|8036|28046|81362|40447|10002,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Spain|Spain|Taiwan|Taiwan|Taiwan",38
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-28,NA,NA,2020-03-24,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 15, 2020",Actual,2020-03-15,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Recruiting,NA,Phase 3,600,Anticipated,Gilead Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:46Z,2020-03-30T09:02:46Z,4284139,NCT04292730,COVID-19,covid-19,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of care therapy per local written policies or guidelines,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Kaiser Permanente Los Angeles Medical Center|Hoag Memorial Hospital Presbyterian|Stanford Hospital|University of Chicago|Brigham & Women's Hospital and Harvard Medical School|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center|Danbury Hospital|Providence St. Vincent Medical Center|The Miriam Hospital|Baylor University Medical Center|Houston Methodist Hospital|Providence Medical Research Center|Swedish Center for Comprehensive Care|MultiCare Tacoma General Hospital|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|ASST degli Spedali Civili di Brescia|ASST di Cremona - Azienda Socio Sanitaria Territor|ASST Fatebenefratelli Sacco|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Clinic de Barcelona|Hospital Universitario Cruces|Hospital Universitario La Paz|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital",Los Angeles|Newport Beach|Stanford|Chicago|Boston|Boston|Lagrangeville|Portland|Providence|Dallas|Houston|Everett|Seattle|Tacoma|Hong Kong|Hong Kong|Hong Kong|Brescia|Cremona|Milano|Padova PD|Pavia|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Barcelona|Bizkaia|Madrid|Kaohsiung|Taichung|Taipei City,California|California|California|Illinois|Massachusetts|Massachusetts|New York|Oregon|Rhode Island|Texas|Texas|Washington|Washington|Washington||||||||||||||||||||,90027|92658|94305|60637|02115|02215|12540|97225|02906|75246|77030|98201|98104|98405||||25123|26100|20157|35121|27100|41944|02053|04564|119228|169856|308442|8036|48903|28046|81362|40447|10002,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Spain|Spain|Spain|Taiwan|Taiwan|Taiwan",34
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-20,NA,NA,2020-03-26,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Estimate,"February 21, 2020",Actual,2020-02-21,"March 20, 2020",2020-03-20,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,440,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T09:03:10Z,2020-03-30T09:03:10Z,4284234,NCT04280705,Corona Virus Infection,corona virus infection,Other|Drug,Placebo|Remdesivir,"The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease|University of California San Diego Health - Jacobs Medical Center|University of California Los Angeles Medical Center - Westwood Clinic|University of California Irvine Medical Center - Infectious Disease|VA Palo Alto Health Care System - Infectious Diseases|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases|University of California Davis Medical Center - Internal Medicine - Infectious Disease|Naval Medical Center San Diego - Infectious Disease Clinic|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine|Denver Health Division of Hospital Medicine - Main Campus|Emory Vaccine Center - The Hope Clinic|Northwestern Hospital - Infectious Disease|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore|Johns Hopkins Hospital - Medicine - Infectious Diseases|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section|Walter Reed Army Institute of Research - Clinical Trials Center|Massachusetts General Hospital - Infectious Diseases|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine|Saint Louis University - Center for Vaccine Development|University of Nebraska Medical Center - Infectious Diseases|Montefiore Medical Center - Infectious Diseases|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology|University of Rochester Medical Center - Vaccine Research Unit|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit|Hospital of the University of Pennsylvania - Infectious Diseases|Vanderbilt University Medical Center - Infectious Diseases|Brooke Army Medical Center|University of Texas Medical Branch - Division of Infectious Disease|Baylor College of Medicine - Molecular Virology and Microbiology|University of Texas Health Science Center at San Antonio - Infectious Diseases|Naval Medical Center Portsmouth - Infectious Disease Division|EvergreenHealth Infectious Disease Service|The University of Washington - Virology Research Clinic|Providence Sacred Heart Medical Center|Madigan Army Medical Center - Infectious Disease Clinic|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center|Seoul National University Bundang Hospital - Division of Infectious Diseases|Seoul National University Hospital|National Centre for Infectious Diseases (NCID)",Birmingham|La Jolla|Los Angeles|Orange|Palo Alto|Palo Alto|Sacramento|San Diego|San Francisco|Denver|Decatur|Chicago|Chicago|Annapolis|Baltimore|Bethesda|Silver Spring|Boston|Minneapolis|Saint Louis|Omaha|Bronx|New York|Rochester|Durham|Philadelphia|Nashville|Fort Sam Houston|Galveston|Houston|San Antonio|Portsmouth|Kirkland|Seattle|Spokane|Tacoma|Tokyo|Bundang-gu Seongnam-si|Seoul|Singapore,Alabama|California|California|California|California|California|California|California|California|Colorado|Georgia|Illinois|Illinois|Maryland|Maryland|Maryland|Maryland|Massachusetts|Minnesota|Missouri|Nebraska|New York|New York|New York|North Carolina|Pennsylvania|Tennessee|Texas|Texas|Texas|Texas|Virginia|Washington|Washington|Washington|Washington||Gyeonggi-do|Jongno-gu|,35233|29037|90095|92868-3298|94304-1207|94304-1503|95817-1460|92314|94110-2859|80204|30030-1705|60611-2908|60612|21401-1527|21287-0005|20892-1504|20910-7500|02114-2621|55455-0341|63104-1015|68198-5400|10467-2401|10016-6402|14642|27704|19104-4238|37232-0011|78234|77555-0435|77030-3411|78229-3901|23708|98034|98104-2433|99204|98431|162-8655|13620|03080|308442,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Japan|Korea, Republic of|Korea, Republic of|Singapore",40
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-10,NA,NA,2020-03-21,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:19Z,2020-03-30T09:02:19Z,4284037,NCT04306393,Coronavirus,coronavirus,Drug,Nitric Oxide Gas,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.
Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-14,NA,NA,2020-03-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"February 16, 2020",Actual,2020-02-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Enrolling by invitation,NA,N/A,60,Anticipated,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:03:21Z,2020-03-30T09:03:21Z,4284270,NCT04273763,Novel Coronavirus Pneumonia,novel coronavirus pneumonia,Drug|Drug|Drug,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,Bromhexine Hydrochloride Tablets|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.,3,,The Second AffIliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-09,NA,NA,2020-03-21,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T09:02:22Z,2020-03-30T09:02:22Z,4284047,NCT04305457,Coronavirus Infections,coronavirus infections,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114-2621,United States,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-27,NA,NA,2020-03-20,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-24,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirus Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirusï¼ˆ2019-nCoVï¼‰ Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:02:51Z,2020-03-30T09:02:51Z,4284148,NCT04291729,2019-nCoV Pneumonia,2019-ncov pneumonia,Drug,Ganovo+ritonavir+/-Interferon nebulization,"Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50Î¼g / time for adults, twice a day up to 14 days.",1,,The Ninth Hospital of Nanchang,Nanchang,Jiangxi,330000,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,A new coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-30T09:02:53Z,2020-03-30T09:02:53Z,4284155,NCT04290871,Coronavirus,coronavirus,Drug,Nitric Oxide Gas,"Inspired NO will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment. After that, NO levels will be decreased to 40 ppm until severe hypoxia resolves. Weaning from NO will start when patients improves the level of oxygenation to a PaO2/FiO2 > 300 mmHg or SpO2 > 93% for more than 24 hours consecutively. Physician will follow their own institutional weaning protocols. In the absence of institutional protocols, NO will be reduced every 4 hours in step-wise fashion starting from 40 ppm to 20, 10, 5, 3, 2 and 1 ppm.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-06,NA,NA,2020-03-22,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"February 6, 2020",Actual,2020-02-06,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:03:43Z,2020-03-30T09:03:43Z,4284369,NCT04261517,Coronavirus,coronavirus,Drug,Hydroxychloroquine,"Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments",1,|,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"February 1, 2022",Anticipated,2022-02-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,New coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T09:02:53Z,2020-03-30T09:02:53Z,4284157,NCT04290858,Coronavirus Infections,coronavirus infections,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,N/A,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:02:23Z,2020-03-30T09:02:23Z,4284052,NCT04305106,COVID-19 Pneumonia,covid-19 pneumonia,Drug,Bevacizumab,"Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-24,NA,NA,2020-03-19,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:57Z,2020-03-30T09:02:57Z,4284170,NCT04288102,Corona Virus Disease 2019(COVID-19),corona virus disease 2019(covid-19),Biological|Biological,MSCs|Saline containing 1% Human serum albuminï¼ˆsolution of MSCï¼‰,"3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.|3 times of placeboï¼ˆintravenously at Day 0, Day 3, Day 6ï¼‰",2,Recruiting|Recruiting,Maternal and Child Hospital of Hubei Province|Wuhan Huoshenshan Hospital,Wuhan|Wuhan,Hubei|Hubei,430000|430000,China|China,2
"ClinicalTrials.gov processed this data on March 05, 2020",2020-02-15,NA,NA,2020-02-20,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit,Recruiting,NA,NA,100,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-06T05:31:12Z,2020-03-06T05:31:12Z,3840666,NCT04279782,Coronavirus,coronavirus,Other,Comprehensive treatment,"Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.",1,Recruiting,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,510630,China,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-05,NA,NA,2020-03-22,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"June 15, 2020",Anticipated,2020-06-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Recruiting,NA,Phase 3,3040,Anticipated,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-30T09:02:29Z,2020-03-30T09:02:29Z,4284075,NCT04304053,COVID-19,covid-19,Drug|Other,Antiviral treatment and prophylaxis|Standard Public Health measures,"darunavir 800 mg / cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4, 5, 6 and 7.
Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.|Isolation of patient and contact tracing as per national guidelines.",2,Recruiting|Recruiting|Recruiting,CAP II Sant FÃ¨lix|GerÃ¨ncia Territorial Catalunya Central|Centre de Salut Isabel Roig-Casernes de Sant Andreu,Sabadell|Sant FruitÃ³s De Bages|Barcelona,Barcelona|Barcelona|,08204|08272|08030,Spain|Spain|Spain,3
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-06,NA,NA,2020-03-25,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Not yet recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-03-30T09:02:30Z,2020-03-30T09:02:30Z,4284076,NCT04303507,COVID19,covid19,Drug|Drug,Chloroquine or Hydroxychloroquine|Placebo,A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months|Placebo,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 27, 2020",2020-02-24,NA,NA,2020-03-23,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 15, 2020",Anticipated,2020-03-15,March 2020,2020-03-31,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,THDMS-COVID19,,"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID19",Not yet recruiting,NA,Phase 3,80,Anticipated,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-03-30T09:02:30Z,2020-03-30T09:02:30Z,4284079,NCT04303299,Coronavirus Infections,coronavirus infections,Drug,Oral,Anti virus treatment,1,,Assistant Professor Subsai Kongsaengdao,Bangkok,,10400,Thailand,1
"ClinicalTrials.gov processed this data on March 27, 2020",2020-03-02,NA,NA,2020-03-19,2020-03-06,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,NA,NA,NA,March 2020,2020-03-31,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Expanded Access Remdesivir (RDV; GS-5734â„¢),Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734â„¢),Available,NA,NA,NA,NA,U.S. Army Medical Research and Development Command,,NA,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-30T09:02:32Z,2020-03-30T09:02:32Z,4284082,NCT04302766,Coronavirus Disease 2019,coronavirus disease 2019,Drug,Remdesivir,"Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-15,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu,"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV",Recruiting,NA,Phase 2,136,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:08:01Z,2020-03-03T05:08:01Z,3751224,NCT04279197,Pulmonary Fibrosis Due to 2019-nCoV,pulmonary fibrosis due to 2019-ncov,Drug|Drug,N-acetylcysteine+ Fuzheng Huayu Tablet|N-acetylcysteine+Placebo,The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.|The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.,2,Recruiting,Shuguang Hospital,Shanghai,Shanghai,201203,China,1
"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-25,NA,NA,2020-02-28,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-28,2020-03-03,Actual,"February 1, 2020",Actual,2020-02-01,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,NA,,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study,Recruiting,NA,NA,15,Anticipated,Shanghai Public Health Clinical Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-14T09:30:12Z,2020-03-14T09:30:12Z,4063942,NCT04292340,Coronavirus,coronavirus,NA,NA,NA,NA,Recruiting,Shanghai Public Health Clinical Center,Shanghai,Shanghai,201508,China,1
"ClinicalTrials.gov processed this data on March 13, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-04,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"April 14, 2021",Anticipated,2021-04-14,"July 14, 2020",Anticipated,2020-07-14,NA,Interventional,NA,,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,NA,N/A,80,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-15T09:18:57Z,2020-03-15T09:18:57Z,4081719,NCT04295551,COVID-19,covid-19,Drug|Drug,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-27,NA,NA,2020-02-29,2020-02-27,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-02-29,2020-03-03,Actual,NA,NA,NA,February 2020,2020-02-29,NA,NA,NA,NA,NA,NA,NA,Expanded Access,SOLID-C19,,Eculizumab (Soliris) in Covid-19 Infected Patients,Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.,Available,NA,NA,NA,NA,Hudson Medical,,NA,NA,NA,FALSE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-14T09:30:50Z,2020-03-14T09:30:50Z,4064083,NCT04288713,Coronavirus,coronavirus,Drug,Eculizumab,A distal complement inhibitor.,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-17,NA,NA,2020-02-18,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-18,2020-02-19,Actual,"February 14, 2020",Anticipated,2020-02-14,February 2020,2020-02-29,"December 14, 2021",Anticipated,2021-12-14,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,NA,,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia",Not yet recruiting,NA,N/A,348,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-01T00:05:07Z,2020-03-01T00:05:07Z,3707743,NCT04275388,2019 Novel Coronavirus Pneumonia,2019 novel coronavirus pneumonia,Drug|Drug,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization","Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-23,NA,NA,2020-02-12,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"December 25, 2020",Anticipated,2020-12-25,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,Steroids-SARI,,Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:43:27Z,2020-02-25T23:43:27Z,3096242,NCT04244591,Coronavirus Infections,coronavirus infections,Drug|Other,methylprednisolone therapy|Standard care,Methylprednisolone 40 mg q12h for 5 days|Standard care,2,Recruiting,"Medical ICU,Peking Union Medical College Hospital",Beijing,Beijing,010,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-01-27,NA,NA,2020-02-25,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-26,Actual,"January 27, 2020",Actual,2020-01-27,February 2020,2020-02-29,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-08T05:21:43Z,2020-03-08T05:21:43Z,3910399,NCT04252118,2019 Novel Coronavirus Pneumonia,2019 novel coronavirus pneumonia,Biological,MSCs,"3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).",1,Recruiting,Beijing 302 Military Hospital of China,Beijing,,100039,China,1
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-19,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients,Recruiting,NA,NA,20,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-03T05:07:41Z,2020-03-03T05:07:41Z,3751147,NCT04279795,Coronavirus,coronavirus,NA,NA,NA,NA,Recruiting,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,510630,China,1
"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-10,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",Not yet recruiting,NA,N/A,160,Anticipated,First Affiliated Hospital of Zhejiang University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:41:29Z,2020-02-25T23:41:29Z,3093793,NCT04261907,2019-nCoV,2019-ncov,Drug|Drug,ASC09/ritonavir group|lopinavir/ritonavir group,"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 19, 2020",2020-02-27,NA,NA,2020-03-09,2020-03-09,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-10,Actual,"March 5, 2020",Anticipated,2020-03-05,February 2020,2020-02-29,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Not yet recruiting,NA,Early Phase 1,24,Anticipated,"CAR-T (Shanghai) Biotechnology Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-20T09:16:55Z,2020-03-20T09:16:55Z,4151360,NCT04302519,COVID-19,covid-19,Biological,Dental pulp mesenchymal stem cells,"On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 13, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-05,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Not yet recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-16T09:09:15Z,2020-03-16T09:09:15Z,4096822,NCT04296643,Coronavirus,coronavirus,Device|Device,Medical Mask|N95 respirator,Medical Mask (known also as Surgical Mask)|N95 respirator,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 27, 2020",2020-02-05,NA,NA,2020-02-13,2020-02-05,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-13,2020-02-17,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"February 4, 2021",Anticipated,2021-02-04,"October 4, 2020",Anticipated,2020-10-04,NA,Observational,Cov-CONTACT,,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Nasopharyngeal swabs
    ",NA,NA,NA,Undecided,NA,2020-02-27T20:37:03Z,2020-02-27T20:37:03Z,3661096,NCT04259892,Coronavirus,coronavirus,Biological,2019-nCoV PCR,Nasopharyngeal swabs,1,Recruiting,CIC 1425,Paris,,75018,France,1
"ClinicalTrials.gov processed this data on March 13, 2020",2020-01-29,NA,NA,2020-03-03,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DACO-nCoV,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-15T09:22:12Z,2020-03-15T09:22:12Z,4082508,NCT04252274,Coronavirus,coronavirus,Drug,Darunavir and Cobicistat,"Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments",1,Recruiting|Recruiting,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,100,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,3751325,NCT04273529,COVID-19 Thalidomide,covid-19 thalidomide,Drug|Drug,thalidomide|placebo,100mgï¼Œpoï¼Œqnï¼Œfor 14 days.|100mgï¼Œpoï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-26,NA,NA,2020-01-26,2020-01-26,2020-01-29,Actual,NA,NA,NA,NA,NA,NA,2020-01-26,2020-01-29,Actual,"January 1, 2020",Actual,2020-01-01,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV",Recruiting,NA,NA,50,Anticipated,Beijing Ditan Hospital,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-02-25T23:43:20Z,2020-02-25T23:43:20Z,3096100,NCT04245631,New Coronavirus,new coronavirus,Diagnostic Test,Recombinase aided amplification (RAA) assay,"We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42Â°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.",1,Recruiting,"Department of Hepatology Division 2, Beijing Ditan Hospital",Beijing,Beijing,100015,China,1
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-13,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for Novel Coronavirus Pneumonia,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:07:25Z,2020-03-03T05:07:25Z,3751092,NCT04280224,Novel Coronavirus Pneumonia,novel coronavirus pneumonia,Biological,NK Cells,twice a week of NK cells (0.1-2*10E7 cells/kg body weight),1,Recruiting,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,453000,China,1
"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-16,NA,NA,2020-02-21,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Not yet recruiting,NA,Phase 1,30,Anticipated,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-03-07T05:30:17Z,2020-03-07T05:30:17Z,3875719,NCT04276987,Coronavirus,coronavirus,Biological,MSCs-derived exosomes,"5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-17,NA,NA,2020-02-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-17,2020-02-19,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,CMHS,,The COVID-19 Mobile Health Study (CMHS),"The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp",Recruiting,NA,NA,450,Anticipated,Chinese Alliance Against Lung Cancer,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The anonymous clinical data for training and validation the model,2020-03-01T00:04:48Z,2020-03-01T00:04:48Z,3707664,NCT04275947,COVID-19,covid-19,Other,"nCapp, a cell phone-based auto-diagnosis system","Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19",1,Recruiting,Renmin Hospital of Wuhan University,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 16, 2020",Anticipated,2020-02-16,February 2020,2020-02-29,"February 15, 2022",Anticipated,2022-02-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Not yet recruiting,NA,N/A,48,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,3751322,NCT04273646,2019 Novel Coronavirus Pneumonia,2019 novel coronavirus pneumonia,Biological|Drug,UC-MSCs|Placebo,"4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).",2,,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-07,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Not yet recruiting,NA,Phase 4,380,Anticipated,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-02-25T23:41:37Z,2020-02-25T23:41:37Z,3093966,NCT04260594,2019-nCoV,2019-ncov,Drug|Other,Arbidol|basic treatment,"Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days|basic treatment",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 18, 2020",Anticipated,2020-02-18,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,40,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,3751324,NCT04273581,COVID-19 Thalidomide,covid-19 thalidomide,Drug|Drug,placebo|Thalidomide,100mg/dï¼Œqnï¼Œfor 14 days.|100mg/dï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-23,NA,NA,2020-02-29,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-29,2020-03-03,Actual,"January 1, 2020",Actual,2020-01-01,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,2019-nCoV,,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV),"Active, not recruiting",NA,NA,400,Anticipated,Fujian Provincial Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-14T09:30:12Z,2020-03-14T09:30:12Z,4063943,NCT04292327,Pneumonia Caused by Human Coronavirus,pneumonia caused by human coronavirus,NA,NA,NA,NA,,Fujian Provincial Hospital,Fuzhou,Fujian,350000,China,1
"ClinicalTrials.gov processed this data on March 09, 2020",2020-02-11,NA,NA,2020-02-26,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-26,2020-02-28,Actual,"February 10, 2020",Actual,2020-02-10,February 2020,2020-02-29,"July 31, 2022",Anticipated,2022-07-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Recruiting,NA,Phase 2,70,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-10T09:11:56Z,2020-03-10T09:11:56Z,3984812,NCT04276688,Novel Coronavirus Infection,novel coronavirus infection,Drug|Drug|Drug,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,400mg/100mg twice daily for 14 days|400mg twice daily for 14 days|0.25mg subcutaneous injection alternate day for 3 days,3,Recruiting,"University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-28,NA,NA,2020-01-30,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-30,2020-02-05,Actual,"January 22, 2020",Actual,2020-01-22,January 2020,2020-01-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:42:38Z,2020-02-25T23:42:38Z,3095192,NCT04251871,Pneumonia Caused by Human Coronavirus (Disorder),pneumonia caused by human coronavirus (disorder),Drug|Drug,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.",2,Recruiting,"The Fifth Medical Center, General Hospital of PLA",Beijing,Beijing,100039,China,1
"ClinicalTrials.gov processed this data on March 05, 2020",2020-01-31,NA,NA,2020-02-20,2020-02-03,2020-02-06,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"May 1, 2020",Anticipated,2020-05-01,"April 3, 2020",Anticipated,2020-04-03,NA,Interventional,NA,,Severe 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.",Recruiting,NA,Phase 3,453,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-06T05:32:37Z,2020-03-06T05:32:37Z,3840978,NCT04257656,2019-nCov,2019-ncov,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Bin Cao,Beijing,Beijing,100029,China,1
"ClinicalTrials.gov processed this data on March 19, 2020",2020-02-24,NA,NA,2020-03-08,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-08,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Observational,NA,,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Completed,NA,NA,8,Actual,Chinese University of Hong Kong,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-20T09:18:58Z,2020-03-20T09:18:58Z,4151849,NCT04285801,COVID-19,covid-19,NA,NA,NA,NA,||,Pamela Youde Nethersole Eastern Hospital|Prince of Wales Hospital|Princess Margaret Hospital,Hong Kong|Hong Kong|Hong Kong,||,||,Hong Kong|Hong Kong|Hong Kong,3
